14-day Premium Trial Subscription Try For FreeTry Free

Is There any Hope for Veru Stock?

09:45am, Saturday, 10'th Dec 2022
The near term looks bad, and it might take a while to get better.

Veru Inc. (VERU) Reports Q4 Loss, Lags Revenue Estimates

12:45pm, Monday, 05'th Dec 2022 Zacks Investment Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

11:30am, Monday, 05'th Dec 2022 GlobeNewswire Inc.
U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS
Veru Inc. (NASDAQ:VERU ) Q4 2022 Earnings Conference Call December 5, 2022 8:00 AM ET Company Participants Brandon Folkes - Cantor Fitzgerald Leland Gershell - Oppenheimer Chris Howerton - Jefferies Y
Veru Inc. (VERU) delivered earnings and revenue surprises of -75.86% and 77.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Veru a Buy?

02:00pm, Friday, 02'nd Dec 2022 The Motley Fool
Or is it just another risky COVID stock?

Is Veru a Buy?

09:00am, Friday, 02'nd Dec 2022
Or is it just another risky COVID stock?
MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncolo
MIAMI, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology

Is It Too Late to Buy Veru Stock?

10:54pm, Wednesday, 23'rd Nov 2022 The Motley Fool
The negative impact of its COVID-19 program faltering will soon be in the past.

Is It Too Late to Buy Veru Stock?

05:54pm, Wednesday, 23'rd Nov 2022
The negative impact of its COVID-19 program faltering will soon be in the past.

Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates

02:15pm, Tuesday, 22'nd Nov 2022 Zacks Investment Research
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Shares of Veru Fell 10.33% on Monday

11:10pm, Monday, 21'st Nov 2022 The Motley Fool
Investors are concerned that approval for a COVID-19 therapy will be delayed or denied.

Why Shares of Veru Fell 10.33% on Monday

06:10pm, Monday, 21'st Nov 2022
Investors are concerned that approval for a COVID-19 therapy will be delayed or denied.

Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates

10:25pm, Monday, 14'th Nov 2022 Zacks Investment Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE